Résumé
Experimental course for integrative life science curriculum is designed for medical students ,which integrates basic knowledge and skills of cellular biology,biochemistry,genetics,molec-ular biology,molecular genetics,and immunology disciplines. Tongji University School of Medicine start-ed to implement integration-based new curriculum system since 2010. This article discussed on teaching philosophy,teaching content,teaching methods,teaching team construction and explored the effect and significance of experimental course for integrative life science curriculum.
Résumé
<p><b>OBJECTIVE</b>To investigate the expression variation of RAR-β2, RASSF1A, and CDKN2A gene in the process of nickel-induced carcinogenesis.</p><p><b>METHODS</b>Nickel subsulfide (Ni(3)S(2)) at dose of 10 mg was given to Wistar rats by intramuscular injection. The mRNA expression of the three genes in induced tumors and their lung metastasis were examined by Real-time PCR. The methylation status of the 5' region of these genes were detected by Quantitative Real-time methylation specific PCR.</p><p><b>RESULTS</b>The mRNA expressions of the three genes both in muscle and lung tumor were decreased distinctly in comparison with normal tissue. But hypermethylation was found only in muscle tumor.</p><p><b>CONCLUSION</b>These findings suggest that loss of function or decrease of RAR-β2, RASSF1A, and CDKN2A, as well as the hypermethylation of 5' region of these genes, are related with nickel exposure.</p>
Sujets)
Animaux , Mâle , Rats , Cancérogènes , Toxicité , Ilots CpG , Inhibiteur p16 de kinase cycline-dépendante , Génétique , Métabolisme , Méthylation de l'ADN , Régulation de l'expression des gènes tumoraux , Tumeurs du poumon , Métabolisme , Tumeurs musculaires , Métabolisme , Nickel , Toxicité , Rat Wistar , Récepteurs à l'acide rétinoïque , Génétique , Métabolisme , Protéines suppresseurs de tumeurs , Génétique , MétabolismeRésumé
Objective To evaluate the effect and safety of combined therapy of paclitaxel and gemcitabine for anthracycine(ANT)-resistant advanced breast cancer(ABC).MethodsFrom May 2000 to Aug 2004,twenty six patients with ANT-resistant ABC were treated with this combined regime.The median chemotherapy cycles were 2.5(range from 2 to 3 cycles).ResultsOf 26 patients, there were 3 complete(11.5%) and 11 partial(42.3%) responses for an overall response rate of 53.8%. Eight cases remained stable (30.8%) and 4 progressive (15.4%). The median survival time was 18 months. The median time to progression was 7 months. The main toxic reaction included bone marrow depression, liver function damage, alopecia, mucositis and peripheral neurotoxicity. ConclusionsCombined medication of gemcitabine and paclitaxel is effective in therapy of ANT-resistant advanced breast cancer with acceptable toxicity.